Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04371419 · ClinicalTrials.gov registry record · NA
COVID-19 Health Messaging to Underserved Communities
A NA study of Coronavirus, sponsored by National Bureau of Economic Research.
- Completed
- Registry status
- NA
- Development phase
- 14,267
- Enrollment target
- 1
- Study location
NCT04371419: Completed NA study of Coronavirus, sponsored by National Bureau of Economic Research.
NCT04371419 is a NA study of Coronavirus that has completed, run by National Bureau of Economic Research. The registered enrollment target is 14,267 participants, above the 692-participant average among 20 other Coronavirus trials with a reported enrollment target (1962% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04371419, a NA study of Coronavirus, has completed, sponsored by National Bureau of Economic Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 14,267 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. The aim of the study is to determine which messages are most effective at increasing knowledge and changing behaviors that can protect individuals and their communities from the virus. To accomplish this aim, we plan to recruit approximately 20,000 Hispanic and African-American individuals and randomly assign them to videos that vary either the sender or the framing of the message, while providing the relevant public health information.
Primary Outcome
Incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 7
Conditions Studied
Interventions
- BEHAVIORAL Messaging
Study Locations (1)
Massachusetts
- JPAL North America - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,267 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2020-05-26 |
| Phase | NA |
What the finished NCT04371419 record still lists
NCT04371419 is an interventional study that assigns participants to a tested intervention. Its 14,267 participants enrollment target places it among the larger protocols in the corpus, above the 692-participant average among 20 other Coronavirus trials with a reported enrollment target (1962% higher).
The record links to 1 condition, with Coronavirus appearing as the primary indexed condition, and to 1 intervention - of which Messaging is the first listed.
NCT04371419 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04371419 about?
NCT04371419 is a clinical study titled "COVID-19 Health Messaging to Underserved Communities". Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. The aim of the study is to determine which messages are most effective at increasing knowledge and changing behaviors that can protect individuals and their commu...
What is the current status of trial NCT04371419?
This trial is currently completed. It is a NA study. The enrollment target is 14,267 participants. The study started on 2020-05-13. Estimated completion is 2020-05-26.
What conditions does trial NCT04371419 study?
This clinical trial studies the following conditions: Coronavirus.
What interventions are being tested in trial NCT04371419?
The interventions under investigation include: Messaging (BEHAVIORAL).
Who is sponsoring clinical trial NCT04371419?
This trial is sponsored by National Bureau of Economic Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04371419 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04371419's enrollment target sits among peer trials
14,267 1st of 20 higher than 20 of 20 other Coronavirus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronavirus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
COMPLETED · NA
-
NOWDx Test for the Detection of Antibodies to COVID-19
COMPLETED · NA
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI